艰难梭菌相关性疾病

参考文献

关键文献

McDonald LC, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis. 2018 Mar 19;66(7):e1-48.全文  摘要

Debast SB, Bauer MP, Kuijper EJ. European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection. Clin Microbiol Infect. 2014 Mar;20(suppl 2):1-26.全文  摘要

Beinortas T, Burr NE, Wilcox MH, et al. Comparative efficacy of treatments for Clostridium difficile infection: a systematic review and network meta-analysis. Lancet Infect Dis. 2018 Sep;18(9):1035-44. 摘要

Nelson RL, Suda KJ, Evans CT. Antibiotic treatment for Clostridium difficile-associated diarrhoea in adults. Cochrane Database Syst Rev. 2017;(3):CD004610.全文  摘要

参考文献

1. Lawson PA, Citron DM, Tyrrell KL, et al. Reclassification of Clostridium difficile as Clostridioides difficile (Hall and O'Toole 1935) Prévot 1938. Anaerobe. 2016 Aug;40:95-9. 摘要

2. McDonald LC, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis. 2018 Mar 19;66(7):e1-48.全文  摘要

3. Poutanen SM, Simor AE. Clostridium difficile-associated diarrhea in adults. CMAJ. 2004 Jul 6;171(1):51-8.全文  摘要

4. Balsells E, Shi T, Leese C, et al. Global burden of Clostridium difficile infections: a systematic review and meta-analysis. J Glob Health. 2019 Jun;9(1):010407.全文  摘要

5. Turner NA, Grambow SC, Woods CW, et al. Epidemiologic trends in Clostridioides difficile infections in a regional community hospital network. JAMA Netw Open. 2019 Oct 2;2(10):e1914149.全文  摘要

6. Lessa FC, Mu Y, Bamberg WM, et al. Burden of Clostridium difficile infection in the United States. N Engl J Med. 2015 Feb 26;372(9):825-34.全文  摘要

7. Marra AR, Perencevich EN, Nelson RE, et al. Incidence and outcomes associated With Clostridium difficile infections: a systematic review and meta-analysis. JAMA Netw Open. 2020 Jan 3;3(1):e1917597.全文  摘要

8. Abrahamian FM, Talan DA, Krishnadasan A, et al; EMERGEncy ID NET Study Group. Clostridium difficile infection among US emergency department patients with diarrhea and no vomiting. Ann Emerg Med. 2017 Jul;70(1):19-27;e4. 摘要

9. Bartlett JG, Perl TM. The new Clostridium difficile - what does it mean? N Engl J Med. 2005 Dec 8;353(23):2503-5. 摘要

10. Loo VG, Poirier L, Miller MA, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med. 2005 Dec 8;353(23):2442-9.全文  摘要

11. McDonald LC, Killgore GE, Thompson A, et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med. 2005 Dec 8;353(23):2433-41.全文  摘要

12. Bartlett JG. Narrative review: the new epidemic of Clostridium difficile-associated enteric disease. Ann Intern Med. 2006 Nov 21;145(10):758-64. 摘要

13. Sheitoyan-Pesant C, Abou Chakra CN, Pépin J, et al. Clinical and healthcare burden of multiple recurrences of Clostridium difficile infection. Clin Infect Dis. 2016 Mar 1;62(5):574-80.全文  摘要

14. Ma GK, Brensinger CM, Wu Q, et al. Increasing incidence of multiply recurrent Clostridium difficile infection in the United States: a cohort study. Ann Intern Med. 2017 Aug 1;167(3):152-8. 摘要

15. Public Health England. C. difficile infection: monthly data by prior trust exposure. Oct 2020 [internet publication].全文

16. European Centre for Disease Prevention and Control. Healthcare-associated infections: Clostridium difficile infections - annual epidemiological report for 2016. Jun 2018 [internet publication].全文

17. Borren NZ, Ghadermarzi S, Hutfless S, et al. The emergence of Clostridium difficile infection in Asia: a systematic review and meta-analysis of incidence and impact. PLoS One. 2017 May 2;12(5):e0176797.全文  摘要

18. Treatment of Clostridium difficile infection. Med Lett Drugs Ther. 2011 Feb 21;53(1358):14-5. 摘要

19. Schroeder MS. Clostridium difficile-associated diarrhea. Am Fam Physician. 2005 Mar 1;71(5):921-8.全文  摘要

20. Miller AC, Segre AM, Pemmaraju SV, et al. Association of household exposure to primary Clostridioides difficile infection with secondary infection in family members. JAMA Netw Open. 2020 Jun 1;3(6):e208925.全文  摘要

21. Teng C, Reveles KR, Obodozie-Ofoegbu OO, et al Clostridium difficile infection risk with important antibiotic classes: an analysis of the FDA Adverse Event Reporting System. Int J Med Sci. 2019 May 7;16(5):630-5.全文  摘要

22. Tariq R, Cho J, Kapoor S, et al. Low risk of primary Clostridium difficile infection with tetracyclines: a systematic review and metaanalysis. Clin Infect Dis. 2018 Feb 1;66(4):514-22. 摘要

23. Dingle KE, Didelot X, Quan TP, et al. Effects of control interventions on Clostridium difficile infection in England: an observational study. Lancet Infect Dis. 2017 Apr;17(4):411-21.全文  摘要

24. Baur D, Gladstone BP, Burkert F, et al. Effect of antibiotic stewardship on the incidence of infection and colonisation with antibiotic-resistant bacteria and Clostridium difficile infection: a systematic review and meta-analysis. Lancet Infect Dis. 2017 Sep;17(9):990-1001. 摘要

25. Blumenthal KG, Lu N, Zhang Y, et al. Risk of meticillin resistant Staphylococcus aureus and Clostridium difficile in patients with a documented penicillin allergy: population based matched cohort study. BMJ. 2018 Jun 27;361:k2400.全文  摘要

26. Blixt T, Gradel KO, Homann C, et al. Asymptomatic carriers contribute to nosocomial Clostridium difficile infection: a cohort study of 4508 patients. Gastroenterology. 2017 Apr;152(5):1031-41;e2. 摘要

27. Miller AC, Segre AM, Pemmaraju SV, et al. Association of household exposure to primary Clostridioides difficile infection with secondary infection in family members. JAMA Netw Open. 2020 Jun 1;3(6):e208925.全文  摘要

28. Cunningham R, Dale B, Undy B, et al. Proton pump inhibitors as a risk factor for Clostridium difficile diarrhoea. J Hosp Infect. 2003 Jul;54(3):243-5. 摘要

29. US Food and Drug Administration. FDA drug safety communication: Clostridium difficile associated diarrhea can be associated with stomach acid drugs known as proton pump inhibitors (PPIs). Feb 2012 [internet publication].全文

30. Arriola V, Tischendorf J, Musuuza J, et al. Assessing the risk of hospital-acquired clostridium difficile infection with proton pump inhibitor use: a meta-analysis. Infect Control Hosp Epidemiol. 2016 Dec;37(12):1408-17.全文  摘要

31. Oshima T, Wu L, Li M, et al. Magnitude and direction of the association between Clostridium difficile infection and proton pump inhibitors in adults and pediatric patients: a systematic review and meta-analysis. J Gastroenterol. 2018 Jan;53(1):84-94. 摘要

32. Cao F, Chen CX, Wang M, et al. Updated meta-analysis of controlled observational studies: proton-pump inhibitors and risk of Clostridium difficile infection. J Hosp Infect. 2018 Jan;98(1):4-13. 摘要

33. Azab M, Doo L, Doo DH, et al. Comparison of the hospital-acquired Clostridium difficile infection risk of using proton pump inhibitors versus histamine-2 receptor antagonists for prophylaxis and treatment of stress ulcers: a systematic review and meta-analysis. Gut Liver. 2017 Nov 15;11(6):781-8.全文  摘要

34. Nguyen GC, Kaplan GG, Harris ML, et al. A national survey of the prevalence and impact of Clostridium difficile infection among hospitalized inflammatory bowel disease patients. Am J Gastroenterol. 2008 Jun;103(6):1443-50. 摘要

35. Razik R, Rumman A, Bahreini Z, et al. Recurrence of Clostridium difficile infection in ptients with inflammatory bowel disease: the RECIDIVISM study. Am J Gastroenterol. 2016 Aug;111(8):1141-6. 摘要

36. Tariq R, Law CCY, Khanna S, et al. The impact of Clostridium difficile infection on mortality in patients with inflammatory bowel disease: a systematic review and meta-analysis. J Clin Gastroenterol. 2019 Feb;53(2):127-33. 摘要

37. Balram B, Battat R, Al-Khoury A, et al. Risk factors associated with Clostridium difficile infection in inflammatory bowel disease: a systematic review and meta-analysis. J Crohns Colitis. 2019 Jan 1;13(1):27-38.全文  摘要

38. Donnelly JP, Wang HE, Locke JE, et al. Hospital-onset Clostridium difficile infection among solid organ transplant recipients. Am J Transplant. 2015 Nov;15(11):2970-7.全文  摘要

39. Paudel S, Zacharioudakis IM, Zervou FN, et al. Prevalence of Clostridium difficile infection among solid organ transplant recipients: a meta-analysis of published studies. PLoS One. 2015 Apr 17;10(4):e0124483.全文  摘要

40. Zacharioudakis IM, Ziakas PD, Mylonakis E. Clostridium difficile infection in the hematopoietic unit: a meta-analysis of published studies. Biol Blood Marrow Transplant. 2014 Oct;20(10):1650-4.全文  摘要

41. Phatharacharukul P, Thongprayoon C, Cheungpasitporn W, et al. The risks of incident and recurrent Clostridium difficile-associated diarrhea in chronic kidney disease and end-stage kidney disease patients: a systematic review and meta-analysis. Dig Dis Sci. 2015 Oct;60(10):2913-22. 摘要

42. Sanchez TH, Brooks JT, Sullivan PS, et al; Adult/Adolescent Spectrum of HIV Disease Study Group. Bacterial diarrhea in persons with HIV infection, United States, 1992-2002. Clin Infect Dis. 2005 Dec 1;41(11):1621-7.全文  摘要

43. Anand A, Glatt AE. Clostridium difficile infection associated with antineoplastic chemotherapy: a review. Clin Infect Dis. 1993 Jul;17(1):109-13. 摘要

44. Southern WN, Rahmani R, Aroniadis O, et al. Postoperative Clostridium difficile-associated diarrhea. Surgery. 2010 Jul;148(1):24-30.全文  摘要

45. Khorasani S, Dossa F, McKechnie T, et al. Association between preoperative oral antibiotics and the incidence of postoperative Clostridium difficile infection in adults undergoing elective colorectal resection: a systematic review and meta-analysis. Dis Colon Rectum. 2020 Apr;63(4):545-61. 摘要

46. Harries RL, Ansell J, Codd RJ, et al. A systematic review of Clostridium difficile infection following reversal of ileostomy. Colorectal Dis. 2017 Oct;19(10):881-7. 摘要

47. Furuya-Kanamori L, Wangdi K, Yakob L, et al. 25-hydroxyvitamin D concentrations and Clostridium difficile infection: a meta-analysis. JPEN J Parenter Enteral Nutr. 2017 Jul;41(5):890-5. 摘要

48. Su GL, Ko CW, Bercik P, et al. AGA clinical practice guidelines on the role of probiotics in the management of gastrointestinal disorders. Gastroenterology. 2020 Aug;159(2):697-705.全文  摘要

49. Goldenberg JZ, Yap C, Lytvyn L, et al. Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children. Cochrane Database Syst Rev. 2017 Dec 19;12:CD006095.全文  摘要

50. Shen NT, Maw A, Tmanova LL, et al. Timely use of probiotics in hospitalized adults prevents Clostridium difficile infection: a systematic review with meta-regression analysis. Gastroenterology. 2017 Jun;152(8):1889-900;e9.全文  摘要

51. Kelly CR, Fischer M, Allegretti JR, et al. ACG clinical guidelines: prevention, diagnosis, and treatment of Clostridioides difficile infections. Am J Gastroenterol. 2021 Jun 1;116(6):1124-47. 摘要

52. Deschênes P, Chano F, Dionne LL, et al. Efficacy of the World Health Organization-recommended handwashing technique and a modified washing technique to remove Clostridium difficile from hands. Am J Infect Control. 2017 Aug 1;45(8):844-8. 摘要

53. Banach DB, Bearman G, Barnden M, et al. Duration of contact precautions for acute-care settings. Infect Control Hosp Epidemiol. 2018 Feb;39(2):127-44.全文  摘要

54. Rutala WA, Weber DJ. Sterilization, high-level disinfection, and environmental cleaning. Infect Dis Clin North Am. 2011 Mar;25(1):45-76. 摘要

55. National Institute for Health and Care Excellence. Infection prevention and control. Apr 2014 [internet publication].全文

56. Macleod-Glover N, Sadowski C. Efficacy of cleaning products for C. difficile: environmental strategies to reduce the spread of Clostridium difficile-associated diarrhea in geriatric rehabilitation. Can Fam Physician. 2010 May;56(5):417-23.全文  摘要

57. Kundrapu S, Sunkesula V, Jury LA, et al. Daily disinfection of high-touch surfaces in isolation rooms to reduce contamination of healthcare workers' hands. Infect Control Hosp Epidemiol. 2012 Oct;33(10):1039-42. 摘要

58. Louh IK, Greendyke WG, Hermann EA, et al. Clostridium difficile infection in acute care hospitals: systematic review and best practices for prevention. Infect Control Hosp Epidemiol. 2017 Apr;38(4):476-82.全文  摘要

59. Barbut F, Menuet D, Verachten M, et al. Comparison of the efficacy of a hydrogen peroxide dry-mist disinfection system and sodium hypochlorite solution for eradication of Clostridium difficile spores. Infect Control Hosp Epidemiol. 2009 Jun;30(6):507-14. 摘要

60. Nerandzic MM, Cadnum JL, Pultz MJ, et al. Evaluation of an automated ultraviolet radiation device for decontamination of Clostridium difficile and other healthcare-associated pathogens in hospital rooms. BMC Infect Dis. 2010 Jul 8;10:197.全文  摘要

61. Ray AJ, Deshpande A, Fertelli D, et al. A multicenter randomized trial to determine the effect of an environmental disinfection intervention on the incidence of healthcare-associated Clostridium difficile infection. Infect Control Hosp Epidemiol. 2017 Jul;38(7):777-83. 摘要

62. Lewis SR, Schofield-Robinson OJ, Rhodes S, et al. Chlorhexidine bathing of the critically ill for the prevention of hospital-acquired infection. Cochrane Database Syst Rev. 2019 Aug 30;8(8):CD012248.全文  摘要

63. Tschudin-Sutter S, Kuijper EJ, Durovic A, et al. Guidance document for prevention of Clostridium difficile infection in acute healthcare settings. Clin Microbiol Infect. 2018 Oct;24(10):1051-4.全文  摘要

64. Arimoto J, Horita N, Kato S, et al. Diagnostic test accuracy of glutamate dehydrogenase for Clostridium difficile: systematic review and meta-analysis. Sci Rep. 2016 Jul 15;6:29754.全文  摘要

65. Deshpande A, Pasupuleti V, Pant C, et al. Potential value of repeat stool testing for Clostridium difficile stool toxin using enzyme immunoassay? Curr Med Res Opin. 2010 Nov;26(11):2635-41.全文  摘要

66. Johnson S, Lavergne V, Skinner AM, et al. Clinical practice guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 focused update guidelines on management of Clostridioides difficile infection in adults. Clin Infect Dis. 2021 Jun 24:ciab549.全文  摘要

67. Debast SB, Bauer MP, Kuijper EJ. European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection. Clin Microbiol Infect. 2014 Mar;20(suppl 2):1-26.全文  摘要

68. Public Health England. Clostridioides difficile infection: guidance on management and treatment. Sep 2019 [internet publication].全文

69. Thabit AK, Alsolami MH, Baghlaf NA, et al. Comparison of three current Clostridioides difficile infection guidelines: IDSA/SHEA, ESCMID, and ACG guidelines. Infection. 2019 Dec;47(6):899-909. 摘要

70. Cho JM, Pardi DS, Khanna S. Update on treatment of Clostridioides difficile infection. Mayo Clin Proc. 2020 Apr;95(4):758-69.全文  摘要

71. National Institute for Health and Care Excellence. Clostridioides difficile infection: antimicrobial prescribing NICE guideline [NG199]. 23 Jul 2021 [internet publication].全文

72. Beinortas T, Burr NE, Wilcox MH, et al. Comparative efficacy of treatments for Clostridium difficile infection: a systematic review and network meta-analysis. Lancet Infect Dis. 2018 Sep;18(9):1035-44. 摘要

73. Okumura H, Fukushima A, Taieb V, et al. Fidaxomicin compared with vancomycin and metronidazole for the treatment of Clostridioides (Clostridium) difficile infection: a network meta-analysis. J Infect Chemother. 2020 Jan;26(1):43-50.全文  摘要

74. Nelson RL, Suda KJ, Evans CT. Antibiotic treatment for Clostridium difficile-associated diarrhoea in adults. Cochrane Database Syst Rev. 2017;(3):CD004610.全文  摘要

75. Khanna S, Shin A, Kelly CP. Management of Clostridium difficile infection in inflammatory bowel disease: expert review from the Clinical Practice Updates Committee of the AGA Institute. Clin Gastroenterol Hepatol. 2017 Feb;15(2):166-74.全文  摘要

76. D'Aoust J, Battat R, Bessissow T. Management of inflammatory bowel disease with Clostridium difficile infection. World J Gastroenterol. 2017 Jul 21;23(27):4986-5003.全文  摘要

77. Cimolai N. Does oral vancomycin use necessitate therapeutic drug monitoring? Infection. 2020 Apr;48(2):173-82. 摘要

78. Ng QX, Loke W, Foo NX, et al. A systematic review of the use of rifaximin for Clostridium difficile infections. Anaerobe. 2019 Feb;55:35-9. 摘要

79. Jaber MR, Olafsson S, Fung WL, et al. Clinical review of the management of fulminant Clostridium difficile infection. Am J Gastroenterol. 2008 Dec;103(12):3195-203;quiz 3204. 摘要

80. Louie TJ, Miller MA, Mullane KM, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med. 2011 Feb 3;364(5):422-31.全文  摘要

81. Stevens VW, Nelson RE, Schwab-Daugherty EM, et al. Comparative effectiveness of vancomycin and metronidazole for the prevention of recurrence and death in patients with Clostridium difficile infection. JAMA Intern Med. 2017 Apr 1;177(4):546-53. 摘要

82. van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 2013 Jan 31;368(5):407-15.全文  摘要

83. Lee CH, Steiner T, Petrof EO, et al. Frozen vs fresh fecal microbiota transplantation and clinical resolution of diarrhea in patients with recurrent Clostridium difficile infection: a randomized clinical trial. JAMA. 2016 Jan 12;315(2):142-9.全文  摘要

84. Hota SS, Sales V, Tomlinson G, et al. Oral vancomycin followed by fecal transplantation versus tapering oral vancomycin treatment for recurrent Clostridium difficile infection: an open-label, randomized controlled trial. Clin Infect Dis. 2017 Feb 1;64(3):265-71.全文  摘要

85. Lai CY, Sung J, Cheng F, et al. Systematic review with meta-analysis: review of donor features, procedures and outcomes in 168 clinical studies of faecal microbiota transplantation. Aliment Pharmacol Ther. 2019 Feb;49(4):354-63. 摘要

86. Du C, Luo Y, Walsh S, et al. Oral fecal microbiota transplant capsules are safe and effective for recurrent Clostridioides difficile infection: a systematic review and meta-analysis. J Clin Gastroenterol. 2021 Apr 1;55(4):300-8. 摘要

87. Kelly CR, Yen EF, Grinspan AM, et al. Fecal microbiota transplantation Is highly effective in real-world practice: initial results from the FMT National Registry. Gastroenterology. 2021 Jan;160(1):183-92.e3.全文  摘要

88. Tariq R, Pardi DS, Bartlett MG, et al. Low cure rates in controlled trials of fecal microbiota transplantation for recurrent Clostridium difficile infection: a systematic review and meta-analysis. Clin Infect Dis. 2019 Apr 8;68(8):1351-8.全文  摘要

89. Rokkas T, Gisbert JP, Gasbarrini A, et al. A network meta-analysis of randomized controlled trials exploring the role of fecal microbiota transplantation in recurrent Clostridium difficile infection. United European Gastroenterol J. 2019 Oct;7(8):1051-63.全文  摘要

90. Moayyedi P, Yuan Y, Baharith H, et al. Faecal microbiota transplantation for Clostridium difficile-associated diarrhoea: a systematic review of randomised controlled trials. Med J Aust. 2017 Aug 21;207(4):166-72.全文  摘要

91. Hvas CL, Dahl Jørgensen SM, Jørgensen SP, et al. Fecal microbiota transplantation is superior to fidaxomicin for treatment of recurrent Clostridium difficile infection. Gastroenterology. 2019 Apr;156(5):1324-32.e3.全文  摘要

92. Tang G, Yin W, Liu W. Is frozen fecal microbiota transplantation as effective as fresh fecal microbiota transplantation in patients with recurrent or refractory Clostridium difficile infection: a meta-analysis? Diagn Microbiol Infect Dis. 2017 Aug;88(4):322-9. 摘要

93. Furuya-Kanamori L, Doi SA, Paterson DL, et al. Upper versus lower gastrointestinal delivery for transplantation of fecal microbiota in recurrent or refractory Clostridium difficile infection: a collaborative analysis of individual patient data from 14 studies. J Clin Gastroenterol. 2017 Feb;51(2):145-50. 摘要

94. Wang S, Xu M, Wang W, et al. Systematic review: adverse events of fecal microbiota transplantation. PLoS One. 2016 Aug 16;11(8):e0161174.全文  摘要

95. Khoruts A, Rank KM, Newman KM, et al. Inflammatory bowel disease affects the outcome of fecal microbiota transplantation for recurrent Clostridium difficile infection. Clin Gastroenterol Hepatol. 2016 Oct;14(10):1433-8.全文  摘要

96. Chen T, Zhou Q, Zhang D, et al. Effect of faecal microbiota transplantation for treatment of Clostridium difficile infection in patients with inflammatory bowel disease: a systematic review and meta-analysis of cohort studies. J Crohns Colitis. 2018 May 25;12(6):710-7.全文  摘要

97. Shogbesan O, Poudel DR, Victor S, et al. A systematic review of the efficacy and safety of fecal microbiota transplant for Clostridium difficile infection in immunocompromised patients. Can J Gastroenterol Hepatol. 2018 Sep 2;2018:1394379.全文  摘要

98. US Food and Drug Administration. Important safety alert regarding use of fecal microbiota for transplantation and risk of serious adverse reactions due to transmission of multi-drug resistant organisms. Jun 2019 [internet publication].全文

99. US Food and Drug Administration. Fecal microbiota for transplantation: safety alert - risk of serious adverse events likely due to transmission of pathogenic organisms. Apr 2020 [internet publication].全文

100. Ianiro G, Murri R, Sciumè GD, et al. Incidence of bloodstream infections, length of hospital stay, and survival in patients with recurrent Clostridioides difficile infection treated with fecal microbiota transplantation or antibiotics: a prospective cohort study. Ann Intern Med. 2019 Nov 19;171(10):695-702.全文  摘要

101. Bafeta A, Yavchitz A, Riveros C, et al. Methods and reporting studies assessing fecal microbiota transplantation: a systematic review. Ann Intern Med. 2017 Jul 4;167(1):34-9. 摘要

102. Hui W, Li T, Liu W, et al. Fecal microbiota transplantation for treatment of recurrent C. difficile infection: an updated randomized controlled trial meta-analysis. PLoS One. 2019 Jan 23;14(1):e0210016.全文  摘要

103. Wilcox MH, Gerding DN, Poxton IR, et al. Bezlotoxumab for prevention of recurrent Clostridium difficile infection. N Engl J Med. 2017 Jan 26;376(4):305-17.全文  摘要

104. Vickers RJ, Tillotson GS, Nathan R, et al. Efficacy and safety of ridinilazole compared with vancomycin for the treatment of Clostridium difficile infection: a phase 2, randomised, double-blind, active-controlled, non-inferiority study. Lancet Infect Dis. 2017 Jul;17(7):735-44.全文  摘要

105. Lee CH, Patino H, Stevens C, et al. Surotomycin versus vancomycin for Clostridium difficile infection: phase 2, randomized, controlled, double-blind, non-inferiority, multicentre trial. J Antimicrob Chemother. 2016 Oct;71(10):2964-71.全文  摘要

106. McCoy RM, Klick A, Hill S, et al. Luminal toxin-binding agents for Clostridium difficile infection. J Pharm Pract. 2016 Aug;29(4):361-7. 摘要

107. Kokai-Kun JF, Roberts T, Coughlin O, et al. Use of ribaxamase (SYN-004), a β-lactamase, to prevent Clostridium difficile infection in β-lactam-treated patients: a double-blind, phase 2b, randomised placebo-controlled trial. Lancet Infect Dis. 2019 May;19(5):487-96. 摘要

108. Bézay N, Ayad A, Dubischar K, et al. Safety, immunogenicity and dose response of VLA84, a new vaccine candidate against Clostridium difficile, in healthy volunteers. Vaccine. 2016 May 17;34(23):2585-92. 摘要

109. ClinicalTrials.gov. Dose-confirmation, immunogenicity and safety study of the Clostridium difficile vaccine candidate VLA84 in healthy adults aged 50 years and older. Phase II study. Jun 2017 [internet publication].全文

110. de Bruyn G, Gordon DL, Steiner T, et al. Safety, immunogenicity, and efficacy of a Clostridioides difficile toxoid vaccine candidate: a phase 3 multicentre, observer-blind, randomised, controlled trial. Lancet Infect Dis. 2021 Feb;21(2):252-62. 摘要

111. Locher HH, Seiler P, Chen X, et al. In vitro and in vivo antibacterial evaluation of cadazolid, a new antibiotic for treatment of Clostridium difficile infections. Antimicrob Agents Chemother. 2014;58(2):892-900.全文  摘要

112. Guery B. Clostridium difficile infection trials: what is the primary endpoint? Lancet Infect Dis. 2019 Mar;19(3):219-20 摘要

113. Almroth S, Mohale M, Latham MC. Grandma ahead of her time: traditional ways of diarrhoea management in Lesotho. J Diarrhoeal Dis Res. 1997 Sep;15(3):167-72. 摘要

114. Brown CC, Manis MM, Bohm NM, et al. Oral vancomycin for secondary prophylaxis of Clostridium difficile infection. Ann Pharmacother. 2019 Apr;53(4):396-401. 摘要

内容使用需遵循免责声明